GlassScriptPhysician profile
John D England
NPI 1427169283
$268,346.64
in general payments reported to CMS, 2019-2025
44 companies · $46K in 2025
The $46K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $18K · 2021: $23K · 2022: $49K · 2023: $52K · 2024: $58K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $106K · Consulting Fee: $25K · Travel and Lodging: $19K · Food and Beverage: $6,212 · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $105,533.76 |
| Consulting Fee | $24,769.38 |
| Travel and Lodging | $18,722.53 |
| Food and Beverage | $6,211.78 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $92,763.29 | 2019-2025 | Gamunex-C |
| Argenx US, INC. | $82,577.79 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Takeda Pharmaceuticals U.S.A., INC. | $54,941.13 | 2020-2025 | Hyqvia, Gammagard Liquid, Gammagard |
| Grifols Shared Services North America, INC. | $13,708.75 | 2019-2025 | Gamunex-C |
| Csl Behring | $12,592.95 | 2019-2024 | Hizentra |
| Shire North American Group INC | $4,951.66 | 2019 | |
| Alexion Pharmaceuticals, INC. | $3,412.90 | 2019-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $338.26 | 2019-2023 | Austedo |
| Novartis Pharmaceuticals Corporation | $307.72 | 2019-2024 | |
| Ucb, INC. | $248.89 | 2020-2025 | Briviact |
| Abbvie INC. | $236.60 | 2021-2025 | |
| Amgen INC. | $215.10 | 2019-2025 | Uplizna |
| Biogen, INC. | $196.53 | 2019-2025 | Leqembi, Vumerity, Tysabri |
| Neurelis, INC. | $177.08 | 2021-2025 | Valtoco |
| Genzyme Corporation | $175.44 | 2019-2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John England listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.